1h Free Analyst Time
The publisher has been monitoring the bile duct cancer market and it is poised to grow by $105.55 mn during 2022-2026, progressing at a CAGR of 7.79% during the forecast period. The report on the bile duct cancer market provides a holistic analysis, market size and forecast, trends, growth drivers, and challenges, as well as vendor analysis covering around 25 vendors.Speak directly to the analyst to clarify any post sales queries you may have.
The report offers an up-to-date analysis regarding the current global market scenario, latest trends and drivers, and the overall market environment. The market is driven by the growing preference for chemotherapy drugs in developing countries and the growing preference for chemotherapy drugs in developing countries.
The bile duct cancer market analysis includes the type segment and geographic landscape.
The bile duct cancer market is segmented as below:
By Type
- Extrahepatic bile duct cancer
- Entrahepatic bile duct cancer
By Geographical Landscape
- North America
- Europe
- Asia
- ROW
This study identifies the new drug approvals as one of the prime reasons driving the bile duct cancer market growth during the next few years.
The report on bile duct cancer market covers the following areas:
- Bile duct cancer market sizing
- Bile duct cancer market forecast
- Bile duct cancer market industry analysis
The robust vendor analysis is designed to help clients improve their market position, and in line with this, this report provides a detailed analysis of several leading bile duct cancer market vendors that include AstraZeneca Plc, BridgeBio Pharma Inc., Bristol-Myers Squibb Co., Hutchison China Meditech Ltd., Incyte Corp., J-Pharma Co. Ltd., Merck KGaA, RemeGen Co. Ltd, Servier, and Sino Biopharmaceutical Ltd. Also, the bile duct cancer market analysis report includes information on upcoming trends and challenges that will influence market growth. This is to help companies strategize and leverage all forthcoming growth opportunities.
The study was conducted using an objective combination of primary and secondary information including inputs from key participants in the industry. The report contains a comprehensive market and vendor landscape in addition to an analysis of the key vendors.
The publisher presents a detailed picture of the market by the way of study, synthesis, and summation of data from multiple sources by an analysis of key parameters such as profit, pricing, competition, and promotions. It presents various market facets by identifying the key industry influencers. The data presented is comprehensive, reliable, and a result of extensive research - both primary and secondary. The market research reports provide a complete competitive landscape and an in-depth vendor selection methodology and analysis using qualitative and quantitative research to forecast the accurate market growth.
Table of Contents
Executive Summary- Market Overview
Market Landscape
- Market ecosystem
- Value chain analysis
Market Sizing
- Market definition
- Market segment analysis
- Market size 2021
- Market outlook: Forecast for 2021 - 2026
Five Forces Analysis
- Bargaining power of buyers
- Bargaining power of suppliers
- Threat of new entrants
- Threat of substitutes
- Threat of rivalry
- Market condition
Market Segmentation by Type
- Market segments
- Comparison by Type
- Extrahepatic bile duct cancer - Market size and forecast 2021-2026
- Intrahepatic bile duct cancer - Market size and forecast 2021-2026
- Market opportunity by Type
Customer landscape
Geographic Landscape
- Geographic segmentation
- Geographic comparison
- North America - Market size and forecast 2021-2026
- Europe - Market size and forecast 2021-2026
- Asia - Market size and forecast 2021-2026
- ROW - Market size and forecast 2021-2026
- Key leading countries
- Market opportunity By Geographical Landscape
- Market drivers
- Market challenges
- Market trends
Vendor Landscape
- Landscape disruption
Vendor Analysis
- Vendors covered
- Market positioning of vendors
- AstraZeneca Plc
- BridgeBio Pharma Inc.
- Bristol-Myers Squibb Co.
- Hutchison China Meditech Ltd.
- Incyte Corp.
- J-Pharma Co. Ltd.
- Merck KGaA
- RemeGen Co. Ltd
- Servier
- Sino Biopharmaceutical Ltd.
Appendix
- Scope of the report
- Currency conversion rates for US$
- Research methodology
- List of abbreviations
List of Exhibits
- Key Finding 1
- Key Finding 2
- Key Finding 3
- Key Finding 5
- Key Finding 6
- Key Finding 7
- Key Finding 8
- Parent market
- Market characteristics
- Offerings of vendors included in the market definition
- Market segments
- Global - Market size and forecast 2021 - 2026 ($ million)
- Global market: Year-over-year growth 2021 - 2026 (%)
- Five forces analysis 2021 & 2026
- Bargaining power of buyers
- Bargaining power of suppliers
- Threat of new entrants
- Threat of substitutes
- Threat of rivalry
- Market condition - Five forces 2021
- Type - Market share 2021-2026 (%)
- Comparison by Type
- Extrahepatic bile duct cancer - Market size and forecast 2021-2026 ($ million)
- Extrahepatic bile duct cancer - Year-over-year growth 2021-2026 (%)
- Intrahepatic bile duct cancer - Market size and forecast 2021-2026 ($ million)
- Intrahepatic bile duct cancer - Year-over-year growth 2021-2026 (%)
- Market opportunity by Type
- Customer landscape
- Market share By Geographical Landscape 2021-2026 (%)
- Geographic comparison
- North America - Market size and forecast 2021-2026 ($ million)
- North America - Year-over-year growth 2021-2026 (%)
- Europe - Market size and forecast 2021-2026 ($ million)
- Europe - Year-over-year growth 2021-2026 (%)
- Asia - Market size and forecast 2021-2026 ($ million)
- Asia - Year-over-year growth 2021-2026 (%)
- ROW - Market size and forecast 2021-2026 ($ million)
- ROW - Year-over-year growth 2021-2026 (%)
- Key leading countries
- Market opportunity By Geographical Landscape ($ million)
- Impact of drivers and challenges
- Vendor landscape
- Landscape disruption
- Industry risks
- Vendors covered
- Market positioning of vendors
- AstraZeneca Plc - Overview
- AstraZeneca Plc - Product and service
- AstraZeneca Plc - Key offerings
- AstraZeneca Plc - Key customers
- AstraZeneca Plc - Segment focus
- BridgeBio Pharma Inc. - Overview
- BridgeBio Pharma Inc. - Product and service
- BridgeBio Pharma Inc. - Key offerings
- BridgeBio Pharma Inc. - Key customers
- BridgeBio Pharma Inc. - Segment focus
- Bristol-Myers Squibb Co. - Overview
- Bristol-Myers Squibb Co. - Product and service
- Bristol-Myers Squibb Co. - Key offerings
- Bristol-Myers Squibb Co. - Key customers
- Bristol-Myers Squibb Co. - Segment focus
- Hutchison China Meditech Ltd. - Overview
- Hutchison China Meditech Ltd. - Business segments
- Hutchison China Meditech Ltd. - Key offerings
- Hutchison China Meditech Ltd. - Key customers
- Hutchison China Meditech Ltd. - Segment focus
- Incyte Corp. - Overview
- Incyte Corp. - Business segments
- Incyte Corp. - Key offerings
- Incyte Corp. - Key customers
- Incyte Corp. - Segment focus
- J-Pharma Co. Ltd. - Overview
- J-Pharma Co. Ltd. - Product and service
- J-Pharma Co. Ltd. - Key offerings
- J-Pharma Co. Ltd. - Key customers
- J-Pharma Co. Ltd. - Segment focus
- Merck KGaA - Overview
- Merck KGaA - Business segments
- Merck KGaA - Key offerings
- Merck KGaA - Key customers
- Merck KGaA - Segment focus
- RemeGen Co. Ltd - Overview
- RemeGen Co. Ltd - Product and service
- RemeGen Co. Ltd - Key offerings
- RemeGen Co. Ltd - Key customers
- RemeGen Co. Ltd - Segment focus
- Servier - Overview
- Servier - Business segments
- Servier - Key offerings
- Servier - Key customers
- Servier - Segment focus
- Sino Biopharmaceutical Ltd. - Overview
- Sino Biopharmaceutical Ltd. - Business segments
- Sino Biopharmaceutical Ltd. - Key offerings
- Sino Biopharmaceutical Ltd. - Key customers
- Sino Biopharmaceutical Ltd. - Segment focus
- Currency conversion rates for US$
- Research Methodology
- Validation techniques employed for market sizing
- Information sources
- List of abbreviations
Executive Summary
The publisher recognizes the following companies as the key players in the global bile duct cancer market: AstraZeneca Plc, BridgeBio Pharma Inc., Bristol-Myers Squibb Co., Hutchison China Meditech Ltd., Incyte Corp., J-Pharma Co. Ltd., Merck KGaA, RemeGen Co. Ltd, Servier, and Sino Biopharmaceutical Ltd.Commenting on the report, an analyst from the research team said: `The latest trend gaining momentum in the market is new drug approvals.`
According to the report, one of the major drivers for this market is the growing preference for chemotherapy drugs in developing countries.
The study was conducted using an objective combination of primary and secondary information including inputs from key participants in the industry. The report contains a comprehensive market and vendor landscape in addition to a SWOT analysis of the key vendors.
Companies Mentioned (Partial List)
A selection of companies mentioned in this report includes, but is not limited to:
- AstraZeneca Plc
- BridgeBio Pharma Inc.
- Bristol-Myers Squibb Co.
- Hutchison China Meditech Ltd. Inc.te Corp.
- J-Pharma Co. Ltd.
- Merck KGaA
- RemeGen Co. Ltd
- Servier
- Sino Biopharmaceutical Ltd.
